DEF 14A

Company

Viking Therapeutics, Inc.

Filed

April 8, 2021

Period of Report

May 20, 2021

Accession Number

0001564590-21-018175

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →